Garder ma session ouverte ?
Expiré dans 
La session est expirée
Votre session a expiré. Pour votre sécurité, VWR vous a déconnecté.
Voulez-vous vous connecter à nouveau?

Same-day whole-plasmid sequencing in your lab

Webinar

Tuesday, 26th April, 2022
15:00 to 16:00 CEST (Berlin, Paris, Madrid)

Replay

Plasmids are a fundamental tool in molecular biology, and verification of the cloned plasmid sequence is essential to ensure that no errors have arisen that may disrupt the expression of inserted genes. Sequencing is the gold-standard approach for clone verification; however, traditional technologies can be limited in regard to turnaround time, primer requirements, sequence bias, sample throughput, and, critically, may preclude the analysis of the whole plasmid construct. Nanopore sequencing overcomes these challenges - offering a fast and cost-effective whole-plasmid sequencing workflow that can be easily implemented in your lab.

In this webinar, you will…

  • Discover the importance of sequencing whole plasmids - not just inserts
  • Learn how to go from purified samples to results in just a few hours - in your own lab
  • Hear how nanopore sequencing allows Vertex Pharmaceuticals to save time and effort in their clone verification workflow and offers the possibility to track sources of contamination
  • Find out how local- or cloud-based analysis keeps your data secure and in house

For more information, please contact us at webinar@avantorsciences.com.

Presented by:

Aaron Pomerantz

Aaron received his PhD from UC Berkeley in the department of Integrative Biology, employing next generation sequencing, genome editing, and bioimaging techniques in non-model organisms. He became a user of Oxford Nanopore Technologies in 2014 to perform in situ DNA sequencing of biodiversity in the Amazon rainforest. In his role as Segment Marketing Manager, he helps drive forward the development of new areas in the research life sciences market.

Jianing Liu

Jianing is a Nucleic Acid Analytics Research Scientist in the gene therapy group at Vertex Pharmaceuticals. She joined Vertex in June 2021 and started her research journey in adeno-associated virus (AAV), where she utilizes long sequencing reads to explore AAV structure and the genomes of production cell lines. As the production of AAV depends on a plasmid transfection of cell culture, quantification of plasmid integrity and purity is key to the reliability of AAV manufacturing.